Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
Showing 541–600 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
…SP was 21mmHg. HRCT Scan confirmed mild ILD.He was commenced on mycophenolate mofetil, amlodipine and omeprazole. Mid-2023 he presented with shortnes…
…ment with low dose prednisolone, mycophenolate, tocilizumab and nifedipine with partial control of her disease. She was on regular follow-…
… baseline HRCT predicted PPF in patients with SSc-ILD receiving mycophenolate or cyclophosphamide therapy. Future independent prospective coh…
…median disease duration 2 years (IQR 1.5-3.5) were treated with teclistamab ( table 1). 3/4 patients suffered from interstitial lung diseas…
…en strongly linked to the underlying disease mechanisms of SSc. Anifrolumab, a Type I IFN receptor inhibitor, is currently approved for pat…
…ith more severe outcomes, and treatment options remain limited. Tibulizumab, an investigational dual-antagonist antibody, designed to neutr…
…e most prescribed IS in ACA- (47%), mainly for ILD (82%), while methotrexate (MTX) predominated in ACA+ (53%), used for cutaneous (44%) or a…
…n TCZ monotherapy, the most common combination therapy was with methotrexate(35%). In SSc-ILD patients, a significant decline of %pFVC from …
… unmet palliative care needs. These findings support the use of ScleroID to capture the spectrum of symptoms and could help determine th…
…nt systemic treatment in both LS (67.9%) and SSc (48%). In SSc, mycophenolate mofetil (38.1%) and cyclophosphamide (14.1%) were also commonly used. B…
…es ANA, anti-Sm and anti-RO 52 were positive. Antimalarials and prednisone were started. One year later, her physical examination showed d…
…esponse was achieved with oral corticosteroids, cyclosporin and Rituximab, almost no response was obtained with MMF and MTX.Owing to the …